Press Release|

Sanofi launches Dupixent® pens with SHL Medical’s Molly® autoinjector technology

News Page

Image Source: “How to take Dupixent”. DUPIXENT, May 2020.

Updated on: June 20, 2020 12 AM EDT

The US FDA approves the 300 mg single-dose 2.0 mL pen presentation of Dupixent®, which is based on SHL Medical’s Molly® 2.25 autoinjector technology, further supporting the convenience self-administration to patients in the US and EU region.

SHL Medical, a leading solutions provider in the self-injection industry, has announced another commercial launch of its Molly® autoinjector family through Sanofi’s Dupixent® pens. The Dupixent® pens are now available for use by patients in the European region.

The Dupixent® pens, available in 1.0 mL and 2.0 mL autoinjector presentations, are built upon SHL Medical’s Molly® technology. A distinct industrial design is featured in both of Sanofi’s Dupixent® pen offerings, which is enabled by Molly®’s flexible design and customization options. The Molly® technology enables an optimized design for manufacturing and can accommodate varying industrial designs to meet client requests, providing the opportunity for product lifecycle management and differentiation in the market.

Sanofi is a global leader in the research, development, and manufacture of pharmaceutical treatments. Sanofi launched Dupixent® in two autoinjector presentations for the European market in March 2020. The commercial launch of the Dupixent® pens marks many firsts in the patient self-administration of complex biologics.

Dupixent® (dupilumab), a fully human monoclonal antibody, is the first and only systemic treatment for atopic dermatitis and is also indicated for asthma. According to research, atopic dermatitis, more commonly referred to as eczema, affects about one-fifth of all individuals during their lifetime.1,2 The product, first approved as a prefilled syringe, is now available to patients in autoinjector presentations. Developed through SHL Medical’s patient-centered design considerations, the pen formats allow for the convenience of self-administration at the comfort of one’s home.

The Dupixent® pen is also the first regulatory approved autoinjector in the high-volume range (≥ 2.0 mL) based on SHL Medical’s Molly 2.25® autoinjector. With a recent trend in the development and approval of complex biologics, the Molly 2.25® autoinjector enables the development of combination products with varying fill volume and viscosity requirements.

“The cooperation with Sanofi to produce both 1.0- and 2.0-mL autoinjector formats of Dupixent® is a monumental milestone for our Molly® autoinjector technology. It has been 10 years since we launched Molly® and it has been continuously supported through a comprehensive infrastructure that allows manufacturing flexibility for various combination product development requirements,” says Josh Gonzalez, Chief Commercial Officer of SHL Medical.

Further information regarding the use of Dupixent® pens can be found here

References:

  1. Cully M, “Atopic dermatitis therapy breakthrough on the horizon?”. Nat Rev Drug Discov, 2011, Vol 13(9), p 645.
  2. Bantz S, Zhu Z, Zheng T, “The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma”. Allergy, Asthma Immunol Res, 2011, Vol 3(2), p 67.
  3. “How to take Dupixent”. DUPIXENT, May 2020: https://www.dupixentmyway.co.uk/atopicdermatitis/about-dupixent/how-to-take-dupixent

About SHL

SHL Group is a world-leading solution provider in the design, development, and manufacturing of advanced drug delivery devices such as autoinjectors, pen injectors and advanced inhaler systems. We also offer core competencies and services in the fields of medtech and patient care solutions. With locations in Taiwan, Switzerland, Sweden, China and the US, our experienced engineers and designers develop product enhancements as well as breakthrough drug delivery and patient care solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of next-generation drug delivery systems that support ongoing innovations in drug development and digital healthcare. This includes advanced reusable and disposable injectors that can accommodate high volume and high viscosities and can be enhanced through digital implementations.

With over 4,800 employees worldwide, SHL Group consists of several distinct group companies:

SHL Medical designs, develops and manufactures advanced drug delivery devices, as well as provides final assembly, labeling and packaging services for leading pharmaceutical and biotech companies across the globe.

SHL Healthcare develops and manufactures equipment solutions for home, hospital and long term care use.

SHL Technologies provides contract manufacturing and engineering services for the production of complex medtech and industrial products.

For additional information, visit www.shl.group

Media contact: info@shl-group.com

Share:

Related News